Literature DB >> 34072328

Primary Gastrointestinal T/NK Cell Lymphoma.

Eun Kyung Kim1, Mi Jang1, Woo Ick Yang2, Sun Och Yoon2.   

Abstract

Primary gastrointestinal T/NK cell lymphoma (GI-TNKL) is an uncommon and heterogeneous group of lymphoid malignancies. We aimed to investigate their subtype distribution, clinicopathologic characteristics, and clinical outcomes. A total of 38 GI-TNKL cases and their clinical and pathological characteristics were analyzed. GI-TNKL occurred in adults with a median patient age in the sixth decade of life and showed a slight male predominance. The most common histologic type was extranodal NK/T-cell lymphoma, nasal type (ENKTL; 34.2%), followed by monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL; 31.6%), intestinal T-cell lymphoma, NOS (ITCL, NOS, 18.4%), anaplastic large cell lymphoma, ALK-negative (ALCL, ALK-; 13.2%). The small intestine was the primary affected region. More than 90% of patients complained of various GI symptoms and cases with advanced Lugano stage, high IPI score, or bowel perforation that required emergent operation were not uncommon. GI-TNKL also showed aggressive behavior with short progression-free survival and overall survival. This thorough clinical and pathological descriptive analysis will be helpful for accurate understanding, diagnosis, and treatment.

Entities:  

Keywords:  T/NK cell lymphoma; clinicopathologic features; gastrointestinal tract; intestinal lymphoma

Year:  2021        PMID: 34072328     DOI: 10.3390/cancers13112679

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  32 in total

1.  Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.

Authors:  Zhao-Yang Wang; Qing-Feng Liu; Hua Wang; Jing Jin; Wei-Hu Wang; Shu-Lian Wang; Yong-Wen Song; Yue-Ping Liu; Hui Fang; Hua Ren; Run-Ye Wu; Bo Chen; Xi-Mei Zhang; Ning-Ning Lu; Li-Qiang Zhou; Ye-Xiong Li
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

2.  Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

Authors:  Michelle A Fanale; Steven M Horwitz; Andres Forero-Torres; Nancy L Bartlett; Ranjana H Advani; Barbara Pro; Robert W Chen; Andrew Davies; Tim Illidge; Dirk Huebner; Dana A Kennedy; Andrei R Shustov
Journal:  J Clin Oncol       Date:  2014-08-18       Impact factor: 44.544

3.  DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.

Authors:  Xin Li; Yingying Cui; Zhenchang Sun; Lei Zhang; Ling Li; Xinhua Wang; Jingjing Wu; Xiaorui Fu; Wang Ma; Xudong Zhang; Yu Chang; Feifei Nan; Wencai Li; Liping Su; Jinghua Wang; Hongwei Xue; Mingzhi Zhang
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

4.  Gastrointestinal Lymphoma in Southwest China: Subtype Distribution of 1,010 Cases Using the WHO (2008) Classification in a Single Institution.

Authors:  Wenshuang Ding; Sha Zhao; Jianchao Wang; Qunpei Yang; Hong Sun; Jiaqi Yan; Limin Gao; Wenqing Yao; Wenyan Zhang; Weiping Liu
Journal:  Acta Haematol       Date:  2015-08-15       Impact factor: 2.195

5.  Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype.

Authors:  S-Y Tan; S-S Chuang; T Tang; L Tan; Y-H Ko; K-L Chuah; S-B Ng; W-J Chng; K Gatter; F Loong; Y-H Liu; P Hosking; P-L Cheah; B-T Teh; K Tay; M Koh; S-T Lim
Journal:  Leukemia       Date:  2013-02-12       Impact factor: 11.528

6.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Authors:  Edgardo R Parrilla Castellar; Elaine S Jaffe; Jonathan W Said; Steven H Swerdlow; Rhett P Ketterling; Ryan A Knudson; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; George Vasmatzis; Sarah E Gibson; Sarah Ondrejka; Alina Nicolae; Karen L Grogg; Cristine Allmer; Kay M Ristow; Wyndham H Wilson; William R Macon; Mark E Law; James R Cerhan; Thomas M Habermann; Stephen M Ansell; Ahmet Dogan; Matthew J Maurer; Andrew L Feldman
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

7.  Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma.

Authors:  Jun Ho Yi; Gyeong-Won Lee; Young Rok Do; Hye Ra Jung; Jung Yong Hong; Dok Hyun Yoon; Cheolwon Suh; Yoon Seok Choi; Seong Yoon Yi; Byeong Seok Sohn; Byung-Su Kim; Sung Yong Oh; Jinny Park; Jae-Cheol Jo; Seung-Sook Lee; Young-Ha Oh; Seok Jin Kim; Won Seog Kim
Journal:  Ann Hematol       Date:  2019-09-06       Impact factor: 3.673

8.  Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Keenan Fenton; Dirk Huebner; Juan M Pinelli; Dana A Kennedy; Andrei Shustov
Journal:  Blood       Date:  2017-10-03       Impact factor: 22.113

9.  STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.

Authors:  Haley M Simpson; Aki Furusawa; Kavitha Sadashivaiah; Curt I Civin; Arnob Banerjee
Journal:  Oncotarget       Date:  2018-03-30

10.  Characteristic gene alterations in primary gastrointestinal T- and NK-cell lymphomas.

Authors:  Gunho Lee; Hyang Joo Ryu; Ji Woon Choi; Hyundeok Kang; Woo Ick Yang; In Seok Yang; Mi-Kyoung Seo; Sangwoo Kim; Sun Och Yoon
Journal:  Leukemia       Date:  2019-01-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.